A clinical trial by ClubStargate for a pill named Ease was suspended because it contained methylone, which was claimed by the Ministry of Health to fall under New Zealand controlled drug analogue laws (although this was never proven in court). Piperazines have been described as ‘failed pharmaceuticals’, as some had been evaluated as potential therapeutic agents by pharmaceutical companies but never brought to the market 1. One piperazine that has been commonly used as NPS is 1-benzylpiperazine (BZP) though other piperazine derivatives have also been reported. These include among others 1-(3-chlorophenyl) piperazine (mCPP), 1-(3-trifluoromethylphenyl) piperazines (TFMPP), 1-benzyl-4-methylpiperazine (MBZP), 1-(4-fluorophenyl) piperazines (pFPP) and 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine (MT-45).
Undesired Effects
The chemical composition of substances sold as piperazines are changing all the time, which is why you can never be sure of what you’re getting and how it could affect you. The stimulant effects of piperazines are similar to MDMA (ecstasy) but dose for dose they are not as potent. (2004), ‘Mass spectra of select benzyl- and phenyl-piperazine designer drugs’, Microgram Journal, Volume 2, Nos 1–4, pp. 22–26. Baumann, M.H., Clark, R.D., Budzynski, A.G., Partilla, J.S., Blough, B.E. (2005), ‘N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-Methylenedioxymethamphetamine (MDMA or ‘Ecstasy’)’, Neuropsychopharmacology, Volume 30, No 3, pp. 550–560. Animal studies have demonstrated that BZP stimulates the release and inhibits the reuptake of dopamine, serotonin and noradrenaline.
Drugs A – Z
Neither BZP nor any other substituted piperazine is listed in the Schedules of the United Nations 1971 Convention on Psychotropic Substances. However, several members of this family have been proposed for critical review by the WHO in 2009. Following a risk assessment in 2007, a Council Decision of 2008 introduced controls on BZP in the European Union. There are no readily-available screening tests for mCPP or the other phenylpiperazine derivatives.
The higher the pH, the longer the retention time of the benzylpiperazine derivatives is. In the case of phenylpiperazine derivatives, the change in pH has little effect on the retention time of these compounds. For the extension of the retention time of the phenylpiperazine derivatives, the percentage of the components of the mobile phase was of the greatest importance. In the determination of piperazine derivatives by the LC-DAD method, all work steps have been optimized.
Typical Users
The presented methods enable the detection of piperazine designer drugs in a different concentration range and additionally in a short time of analysis. Rapid analytical confirmation of the cause of poisoning is essential in medical interventions that save human health and life. The proposed methods may be useful techniques in situations requiring analytical confirmation of piperazine designer drug poisoning and may be helpful in comprehensive toxicological diagnostics. The available literature and data indicate an increasing number and chemical diversity of new psychoactive substances (NPS), also known as designer drugs 1,2,3. Products of this type are advertised as a modern alternative to illegal drugs, the possession and sale of which is prohibited by law 4,5.
8 LC-DAD Analysis—Validation Of The Method
Further work is necessary to determine the precise mechanism(s) underlying the apparent synergism between BZP and TFMPP. These compounds are seen by users as alternatives to MDMA and amphetamines due to their similar effects on the central nervous system. The recreational use of piperazine derivatives can result in acute or chronic poisoning. The article describes methods using liquid chromatography techniques for the independent detection of piperazine designer drugs in biological and non-biological matrices.
Confirmation of the presence of piperazine designer drugs in biological material (urine, serum). Chemical structures, precursor ions, M + H+ and fragmentation patterns of piperazine designer drugs observed in LC-MS. Two separate studies, one by Bye et al (1973) and Campbell et al in the same year were conducted in order to assess the amphetamine-like effects of the drug.
How Is BZP Used?
Comparing CL int values thus obtained, we concluded that 2C19 could be predominant for metabolic activity on tricyclic antidepressants as expected, but not on phenothiazine-related antipsychotic drugs. Since the metabolism of CNS drugs is susceptible to single nucleotide polymorphisms of human gene, our results suggest that phenothiazine could be an alternative to clinical application of CNS drugs. From the ethical as well as rational reasons, the selection of an appropriate system is crucial.
Latest Data
The present in vitro data confirm that MDMA is a monoamine-releasing agent that acts as a substrate for DATs and SERTs in nervous tissue (reviewed by Green et al, 2003). In a side-by-side comparison with MDMA, we demonstrated that BZP is a releaser of 3HMPP+, whereas TFMPP is a releaser of 3H5-HT. Similar to MDMA, the in vitro releasing properties of BZP and TFMPP are mediated by substrate activity at DATs and SERTs, since low doses of selective transporter blockers can antagonize the effects of these piperazines (see Figures 2 and 3).
These results suggest that stimulation of SERT-mediated 5-HT release alone (ie in the absence of concurrent DA release) may not be sufficient to produce robust motor activation. We have shown that fenfluramine and chlorphentermine are relatively selective 5-HT releasers in vivo, and these drugs do not produce locomotor stimulation (Baumann et al, 2000; Rothman and Baumann, 2000). Alternatively, the direct postsynaptic receptor actions of TFMPP may serve to inhibit behavior. It is known that TFMPP decreases spontaneous activity in rats exposed to a novel environment (Lucki et al, 1989), and such hypomotility is mediated via activation of 5-HT2C receptors. It is feasible that TFMPP did not decrease motor activity in our experiments because rats were already habituated to housing conditions with an overnight acclimation period.
- Because piperazines can dissolve fats, they are often used as cleaning solutions.
- To the best of our knowledge, the present findings with BZP are the first demonstration of DAT substrate activity for this compound.
- Objectives ‘Party pills’ have found use worldwide as a substitute for amphetaminederived designer drugs.
- The other two isomers of CPP could be made in a similar way.It is unlikely that the mCPP found in illicit products has been synthesised in clandestine laboratories since it is available commercially as the base or as the hydrochloride salt.
- First, as shown in Table 1, high-dose BZP/TFMPP produced a smaller rise in dialysate 5-HT (872%) when compared to high-dose MDMA (1445%), yet BZP/TFMPP increased extracellular DA levels about four-fold more than MDMA.
Medical Usage
The placement of microdialysis probe tips within the nucleus accumbens was verified by visual inspection, and only rats with correct placements were included in the data analyses. Preclinical studies show that high-dose administration of MDMA causes long-term changes in central 5-HT systems (Lyles and Cadet, 2003). These changes include depletions of tissue 5-HT, inactivation of tryptophan hydroxylase, and loss of SERT binding sites in terminal fields throughout the forebrain. Taken together, these data suggest that MDMA produces 5-HT neurotoxicity in animals.
The negative effects of mCPP, often typical of a serotonin syndrome, include anxiety, dizziness, confusion, shivering, sensitivity to light and noise, fear of losing control, migraine and panic attacks. The subjective effects of mCPP and MDMA are somewhat comparable, but unlike MDMA and BZP, mCPP has little effect on the dopaminergic system. A major aim of the present investigation was to examine the neurochemical effects of BZP and TFMPP, when administered alone and in combination. An additional goal was to compare the effects of these N-substituted piperazines with the ring-substituted amphetamine, MDMA. Increasing evidence indicates that misuse of BZP and TFMPP is rising in the US and abroad (de Boer et al, 2001; Drug Enforcement Administration, 2001; Maurer et al, 2004; Wikstrom et al, 2004). In the US, for example, law enforcement officials from Federal, state and local jurisdictions have reported a marked increase in the number of confiscated tablets containing BZP and/or TFMPP.
There are no licensed medicinal products in the EU containing BZP or any of the other substances considered here. In the presented studies, analyses were performed using the buffer concentrations of 10 mM, 20 mM and 100 mM. Using a concentration of 10 mM, the obtained results were not satisfactory.
In Europe, BZP—which is known there as A2—is marketed “as a cheap and safe alternative compared to illicit amphetamines,” stated a DEA “Drug Intelligence Brief” released in December of 2001. As late as 2005, the drug was being sold over-the-counter in New Zealand as a legal stimulant under the brand name Nemesis. “The pills… are advertised as safe, legal alternatives to illegal highs. There is no age restriction on sales,” according to a drug authority interviewed in the Ashburton Guardian. As of 2005, use among humans was limited to the treatment of parasitic worm infections. (1973), ‘A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests’, European journal of clinical pharmacology, Volume 6, No 3, pp. 163–169.
Although the extent of piperazine abuse is impossible to ascertain, the DEA has placed BZP and TFMPP into emergency Schedule I status based on the potential for imminent hazard to public safety (Department of Justice, 2002). In recent years, the number of new psychoactive substances (NPS) appearing on the illicit drug market strongly increased. Therefore, we determined the most frequently occurring NPS in The Netherlands and combined this with data regarding drug-related intoxications. Data from the Drugs Information and Monitoring System (DIMS) and the Dutch Poisons Information Centre (DPIC) were combined and jointly analyzed. The number of drug samples submitted to DIMS for analysis containing NPS increased from 22 in 2007 to 431 samples in 2013. The most frequently submitted NPS in 2013 included 4-bromo-2,5-dimethoxyphenethylamine (2C-B), 4-fluoroamphetamine (4-FA), methoxetamine (MXE) and 6-(2-aminopropyl)benzofuran (6-APB).
